Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:26:40.892Z.
Calculation as of: 2026-10-06T16:26:40.892Z.
Quote observation: 2026-10-06T16:24:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869772d5b15fe2f366f7470de3318cdd420f1d22994776f46b79eb6f67ec6a89
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Eupraxia Pharmaceuticals Inc.
Market Cap
$266.50M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.05M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.44M
Price/FCF Ratio
N/A
TTM Avg
4.69
3Y Avg
5.94
5Y Avg
441.51
Market Cap
$267.03M
Price/FCF Ratio
N/A
TTM Avg
61.29
3Y Avg
61.29
5Y Avg
61.29
Market Cap
$263.05M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.23M
Price/FCF Ratio
459.48
TTM Avg
239.45
3Y Avg
256.85
5Y Avg
209.66
Market Cap
$274.62M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $266.50M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.05M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $266.44M | N/A | 4.69 | 5.94 | 441.51 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.03M | N/A | 61.29 | 61.29 | 61.29 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $263.05M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | N/A | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $273.40M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.23M | 459.48 | 239.45 | 256.85 | 209.66 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $256.72M | N/A | 5.28 | 5.50 | 5.50 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
